Evaluating Innovative Therapies Access in Portugal

According to Paulo Gonçalves in the APIFARMA newsletter, Innovative Therapies Access in Portugal directs resources toward therapeutic innovation at levels substantially below feasible ambitions. Protracted authorization processes impose measurable costs on individual health trajectories, societal welfare, and macroeconomic productivity.

Organizational reforms have created essential scaffolding through integrated local health units and centralized digital infrastructure. These gains now demand active process redesign to deliver tangible improvements.

Human Cost of Every Delayed Day

The Patient Waiting to Access Innovative Therapies (W.A.I.T.) indicator keeps Portugal near the bottom of European rankings. Each extra month of delay translates into accumulated disease progression rather than simple administrative time.

Degenerative conditions rob patients of irrecoverable mobility and function. In certain rare diseases, patients die before regulatory clearance arrives.

Joint European Assessments Cutting Redundant Work

Harmonized health technology assessment (HTA) mechanisms will allow two member states to conduct joint scientific reviews. This approach compresses timelines and reduces duplicated national efforts.

The pending National System for Health Technology Assessment (SiNATS) and its Information System for Health Technology Assessment (SIATS) will enforce transparency and accountability in economic evaluations. Centralized national decision-making will replace fragmented hospital-level price negotiations.

Digital Monitoring Exposing Persistent Postcode Inequality

Continental benchmarking still shows Portugal’s stagnant performance on time-to-access metrics. Postcode-driven variation persists despite the statutory universality of the National Health Service.

Centralized cost and outcome registries could eliminate this inefficiency and inequity. Expanded functionality of the regulatory authority’s process-tracking tool, once SiNATS is approved, is expected to deliver measurable gains.

Clinical Trials as Regulated Early Access

Clinical trial participation offers a regulated form of early access, especially valuable for patients without alternatives. The unified electronic health record (RSEu) now enables cohort identification within days and near-immediate specialist notification.

The rare-disease identification card gains real power only when embedded in the RSEu. Integration triggers automatic alerts for emergency teams and fast connection to European reference networks.

Scaling Supranational Collaboration for Faster Reimbursement

Consolidating economic negotiations at European scale for roughly 500 million citizens could replace redundant national processes while protecting timely access. Until then, assigning pricing responsibility to a single national authority would shorten delays and equalize availability across Portugal.

Patient advocacy organizations are preparing to join economic discussions, drawing on European best-practice forums. Positioning within the European Health Data Space will integrate Portuguese centers into virtual specialist networks that prioritize complementary expertise over duplication.

These changes will reshape health economics and outcomes research by requiring models grounded in real-world evidence from unified registries. Such reforms ultimately strengthen Innovative Therapies Access in Portugal without compromising the universality principle that defines the Portuguese health system.